阿帕替尼联合紫杉醇在肺癌患者中的疗效分析

Efficacy Analysis of Apatinib Combined with Paclitaxel for Lung Cancer Patients

目的探究阿帕替尼联合紫杉醇对肺癌患者的疗效及其对肺功能的影响。方法选取我院收治的肺癌患者120例,根据治疗方法不同分为对照组和观察组。对照组采用紫杉醇单药治疗,观察组采用阿帕替尼联合紫杉醇治疗。比较两组患者的治疗效果、不良反应及细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、基质金属蛋白酶9(MMP-9)、血管内皮生长因子(VEGF)水平。结果观察组的治疗效果明显高于对照组(P<0.05),不良反应发生率显著低于对照组(P<0.05)。治疗后,观察组CYFRA21-1、CEA、MMP-9、VEGF水平均显著低于对照组(P<0.05)。结论对肺癌患者使用阿帕替尼联合紫杉醇进行治疗,可取得良好的治疗效果,且安全性高,不良反应少,值得临床上进一步推广和应用。

Objective To explore the efficacy of apatinib combined with paclitaxel in patients with lung cancer and the influence on pulmonary function after treatment. Methods A total of 120 cases of lung cancer treated in our hospital were divided into two groups according to the different treatment methods. Patients in control group were treated with paclitaxel, and those in observation group were treated with apatinib and paclitaxel. Detect the cytokeratin 19 fragment(CYFRA21-1), Carcinoembryonic antigen(CEA), matrix metalloproteinase 9(MMP-9) and vascular endothelial growth factor(VEGF) levels, and compare the therapeutic effect and prognosis between the two groups. Results The therapeutic effective rate of the observation group was significantly higher than that of the control group(P<0.05).The incidence of the adverse reactions of the observation group were lower than those of the control group(P<0.05). After treatment, the levels of CYFRA21-1, CEA, MMP-9 and VEGF in the observation group were significantly lower than those of the control group(P<0.05).Conclusion The combined use of apatinib and paclitaxel for lung cancer patients has achieved good therapeutic effect, high safety and less adverse reactions. It is worthy of further popularization and application in clinic.